Therapy News and Research

RSS

FDA grants IDE approval for Apnex HGNS System to treat obstructive sleep apnea

Apnex Medical, Inc., received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a clinical study to evaluate the safety and effectiveness of its Hypoglossal Nerve Stimulation System to treat obstructive sleep apnea.

3 Aug 2011

Lipid nanocarriers in cancer diagnosis and therapy: New book

This book introduces fundamental principles of lipid nanocarriers science relevant to cancer therapy. The first in this field, it fills a need for an accurate, coherent and authoritative introduction to lipid nanocarriers focusing in cancer therapy; both because of the growing popularity of these modern drug delivery systems and also because of the emergent need of dealing with cancer treatment.

2 Aug 2011

A guide to safe and informed recovery after prostate cancer

Prostate cancer is the number two killer of American men, second only to lung cancer. It is a disease that affects more than 2 million American men, and in 2010 there were over 218,000 new diagnoses.

2 Aug 2011

Enrollment commences in St. Jude Medical's atrial fibrillation stroke prevention trial

St. Jude Medical, Inc., a global medical device company, today announced that the first patient was enrolled in the EAST (Early comprehensive Atrial fibrillation Stroke prevention Trial) clinical trial.

2 Aug 2011

MindFrame receives CE mark approval for Capture LP and Flow LP devices

MindFrame Inc. today announces receiving CE mark approval for the MindFrame Capture LP™ and MindFrame Flow LP™ devices. Part of the comprehensive portfolio of MindFrame Therapy Solutions™, these low profile devices can be deployed through a smaller microcatheter to improve access through tortuous vessel anatomies.

2 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Nursing homes to face Medicare pay cut

The Centers for Medicare and Medicaid Services finalized an 11 percent drop in nursing home payments, which will kick in next year.

2 Aug 2011

NYU Langone receives NHLBI grant for comparative effectiveness ISCHEMIA Trial

NYU Langone Medical Center announced it has received an $84 million grant from the National Heart, Lung, and Blood Institute (NHLBI), of the National Institutes of Health (NIH), to study the comparative effectiveness of two initial management strategies for patients with coronary artery disease.

2 Aug 2011

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Are you genetically predisposed to tuberculosis? Scientists may now be able to answer this question and doctors may be able to adjust their therapeutic approach based on what they learn. That's because new research presented in the Journal of Leukocyte Biology suggests that two frequent mutations in an immune system gene called TLR1 are responsible for cellular changes that ultimately make us less likely to resist the disease.

2 Aug 2011

Positive results from Jennerex JX-594 proof-of-concept trial on metastatic melanoma

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.

2 Aug 2011

ADA releases new position paper, 'Nutrition Intervention in the Treatment of Eating Disorders'

As one of the most complicated sets of illnesses to treat, eating disorders have mental health, as well as medical and nutritional, aspects. While treatment by a multidisciplinary health-care team is considered the best practice, there is considerable debate over how to most effectively treat eating disorders and who should be on a treatment team.

2 Aug 2011

New insight into causes of pronoun confusion in autism

Autism is a mysterious developmental disease because it often leaves complex abilities intact while impairing seemingly elementary ones. For example, it is well documented that autistic children often have difficulty correctly using pronouns, sometimes referring to themselves as "you" instead of "I."

2 Aug 2011

Roundup: Calif.'s health-budget cuts; new med school for rural docs; community health centers packed

Faced with years of recession-driven budget shortfalls, state lawmakers have made deep cuts to health and social services. The reductions, including a round that took effect this month, translate into sizable state savings but are sharply scaling back the safety net for California's most vulnerable residents: the elderly, the disabled and the poor.

2 Aug 2011

New endoscopic OCT system enables 3-D imaging of esophagus, colon cancers

Researchers at the Massachusetts Institute of Technology (MIT) have developed a new imaging system that enables high-speed, three-dimensional (3-D) imaging of microscopic pre-cancerous changes in the esophagus or colon.

2 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011

Auxilium second quarter net loss decreases to $5.1 million

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended June 30, 2011. For the second quarter of 2011, Auxilium reported net revenues of $65.9 million compared to net revenues of $50.5 million in the second quarter of 2010.

1 Aug 2011

FDA approves Covidien's morphine sulfate oral solution for chronic pain in opioid-tolerant patients

Covidien, a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) recently granted approval to the company's Mallinckrodt business for morphine sulfate oral solution, used to relieve moderate to severe acute and chronic pain in opioid-tolerant patients. The solution will be available as a generic in 100 milligrams per 5 mL (20 milligrams per 1 mL).

1 Aug 2011

Cubist initiates CXA-201 Phase 3 trial in complicated urinary tract infections

Cubist Pharmaceuticals, Inc. today announced the initiation of a pivotal Phase 3 trial of CXA-201 in patients with complicated urinary tract infections.

1 Aug 2011

PathoGenetiX receives $4.0 million in first close of Series B financing

PathoGenetiX Inc., today announced that the Company has received $4.0 million in the first closing of its Series B financing.

1 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011